WHO ICTRP trial
Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of…
NL-OMON45999 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON45999 |
|---|---|
| Public title | Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer. |
| Scientific title | Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer. - PROpel |
| Primary sponsor | Astra Zeneca |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | Australia;Belgium;Brazil;Canada;Chile;China;Czechia;France;Germany;Italy;Japan;Korea (the Republic of);Netherlands;Slovenia;Spain;Turkey;United Kingdom;United States of America |
| Conditions | metastatic castration resistant prostate cancer prostate cancer;10036958;metastatic castration resistant prostate cancer;prostate cancer |
| Interventions | Patients receive treatment with Olaparib 300 mg twice daily and abiraterone acetate 1000 mg with 5 mg bid prednisone or Patients receive treatment with Placebo twice daily and abiraterone acetate 1000 mg with 5 mg bid prednisone… |
| Registration date | Mar 27, 2019 |
| Target size | 25 |
| Secondary IDs | 2018-002011-10;NL67082.091.18 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: